Awakn Life Sciences Corp. announced the launch of an additional Licensing Partnership agreement in North America. The agreement is with Rivus Wellness and Research Institute ("Rivus"), based in Oklahoma City.

This is the first Licensing Partnership Awakn has in the U.S. southern states, opening up a whole new population and geographic region to the Awakn Kare treatment. Awakn Kare is a proprietary treatment protocol developed and validated in a phase II a/b trial. The trial delivered 86% abstinence over the six months post-treatment versus 2% pre-trial.

This efficacy is significantly better than the current standard of care for AUD which has an approximate 25% abstinence rate over a similar timeframe. Under the terms of the license agreement, signed May 18, 2023, and launched April, 2024, Awakn provides access to its proprietary therapeutics and training to the Rivus practitioners, and in return, Rivus will pay Awakn an annual fee and a revenue share per treatment. The U.S. alcohol and substance addiction treatment industry is significant in size with 14,000+ treatment facilities across the country1, with direct medical costs in the region of US30 billion per annum2 but with relatively poor treatment success rates.

Awakn aims to improve the performance of the addiction industry by providing its license partners and clinic operators with access to an efficient and more effective treatment option under license.